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In view of the rising global burden of diabetes and obesi-
ty the International Federation of Gynecology and Obstetrics 
(FIGO) embarked on a new initiative in 2014 to raise aware-
ness about the link between hyperglycemia in pregnancy 
(HIP) and poor maternal and fetal outcomes, and the risk 
to the future health of both the mothers with HIP and their 
offsprings. To achieve this FIGO brought together a group 
of experts to frame the issues and develop a document 
suggesting key actions to address the public health burden 
posed by HIP. The FIGO “Initiative on gestational diabetes 
mellitus: A pragmatic guide for diagnosis, management, 
and care” was launched at FIGO World Congress in October 
2015 in Vancouver and published as a special supplement of 
the International Journal of Gynecology and Obstetrics [1]. 
The document provides pragmatic guidance for testing, 
management and care of women with GDM regardless of 
resource settings and calls for a clearly defined global health 
agenda to tackle the issue. 
Despite challenges of providing guidance in the set-
ting of limited high-quality evidence, particularly from the 
developing world, the document outlines up to date global 
standards for testing, management, and care of women with 
GDM and provides pragmatic recommendations: which due 
to their feasibility, acceptability, and ease of implemen-
tation, have the potential to produce significant impact. 
Suggestions are provided for a variety of different regional 
financial, human, and infrastructure resource settings. The 
document also outlines research priorities to bridge the 
current knowledge and evidence gap. 
Prior to publication, the document was widely circulated 
for evaluation and received support from many interna-
tional groups such as the European Board and College of 
Obstetrics and Gynaecology (EBCOG), The Society of Obste-
tricians and Gynecologists of Canada (SOGC), Chinese Soci-
ety of Perinatal Medicine, Diabetic Pregnancy Study Group 
(DPSG), African Federation of Obstetrics and Gynaecology 
(AFOG), South Asian Federation of Obstetrics and Gyne-
cology (SAFOG), Australian Diabetes in Pregnancy Society 
(ADIPS), International Association of Diabetes in Pregnancy 
Study Groups (IADPSG), European Association of Perinatal 
Medicine (EAPM), International Diabetes Foundation (IDF), 
Diabetes in Pregnancy Study Group of India (DIPSI), and the 
Diabetes in Pregnancy Study Group of Latin America, in ad-
dition to the executive board and other relevant committees 
and working groups within FIGO. 
While the document has been welcomed and well re-
ceived globally, implementing the recommendations on 
the ground in the diverse global settings requires advocacy 
and awareness raising, building capacity and addressing 
the knowledge gaps including operational research and 
generating health economics evidence. This is the challenge 
that FIGO plans to address in the next phase. 
A summary of the main areas of focus are provided 
below though we strongly suggest reading the original 
document which is open access and can be found here: 
www.figo.org/figo-project-publications. Hereby, we list the 
exact quotes on the matter from the paper: The International 
Federation of Gynecology and Obstetrics (FIGO) Initiative 
on Gestational Diabetes Mellitus: A Pragmatic Guide for 
Diagnosis, Management, and Care published in Interna-
tional Journal of Gynecology and Obstetrics 131 S3 (2015) 
S173–S211:
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GESTATIONAL DIABETES MELLITUS
The occurrence of GDM parallels the prevalence of im-
paired glucose tolerance (IGT), obesity, and type 2 diabetes 
mellitus (T2DM) in a given population. These conditions are 
on the rise globally. Moreover, the age of onset of diabetes 
and pre-diabetes is declining while the age of childbearing is 
increasing. There is also an increase in the rate of overweight 
and obese women of reproductive age; thus, more women 
entering pregnancy have risk factors that make them vulner-
able to hyperglycemia during pregnancy [1]. 
It should therefore not be surprising that hyperglycemia 
is one of the most common medical conditions during preg-
nancy; an estimated one in seven live births globally (16.8%) 
are to women with some form of hyperglycemia in pregnancy. 
While 16% of these cases may be due to diabetes in pregnancy 
(either pre-existing diabetes — type 1 or type 2 — which ante-
dates pregnancy or is first identified during testing in the index 
pregnancy), the majority (84%) are due to gestational diabetes 
mellitus (GDM) [1, 2]. 
GDM is associated with higher incidence of maternal 
morbidity including cesarean deliveries, shoulder dystocia, 
birth trauma, hypertensive disorders of pregnancy (including 
pre-eclampsia), and subsequent development of T2DM. Peri-
natal and neonatal morbidities also increase; the latter include 
macrosomia, birth injury, hypoglycemia, polycythemia, and 
hyperbilirubinemia. Long-term sequelae in offspring with in 
utero exposure to maternal hyperglycemia may include higher 
risks for obesity and diabetes later in life [1]. 
Given the interaction between hyperglycemia and poor 
pregnancy outcomes, the role of in utero imprinting in increas-
ing the risk of diabetes and cardio-metabolic disorders in the 
offspring of mothers with hyperglycemia in pregnancy, as well 
as increasing maternal vulnerability to future diabetes and 
cardiovascular disorders, there needs to be a greater global 
focus on preventing, screening, diagnosing, and managing 
hyperglycemia in pregnancy. The relevance of GDM as a prior-
ity for maternal health and its impact on the future burden of 
non-communicable diseases is no longer in doubt; but how 
best to deal with the issue remains contentious as there are 
many gaps in knowledge on how to prevent, diagnose, and 
manage GDM to optimize care and outcomes. These must be 
addressed through future research [1].
Global healthcare organizations and professional bodies 
have advocated a plethora of diverse algorithms for screening 
and diagnosis of GDM which have been criticized for lacking 
validation, such as they were developed based on tenuous data, 
the result of expert opinions, biased owing to economic consid-
erations, or convenience-oriented, thereby creating confusion 
and uncertainty among care providers  [3]. One underlying 
yet fundamental problem, as shown consistently by several 
studies including the Hyperglycemia and Adverse Pregnancy 
Outcomes (HAPO) study [4], is that the risk of poor pregnancy 
outcomes associated with hyperglycemia is continuous with 
no clear inflection points. It is therefore clear that any set of 
criteria for the diagnosis of GDM proposed will need to evolve 
from a consensus approach, balancing risks and benefits in 
particular social, economic, and clinical contexts. As well as 
different cut-off values, the lack of consensus among the dif-
ferent professional bodies for an algorithm for screening and 
diagnosis of GDM is perhaps an even larger problem [1]. 
In most parts of low and middle income countries 
(LMICs) (which contribute to over 85% of the annual global 
deliveries), the majority of women are not screened for 
diabetes during pregnancy — despite the fact that these 
countries account for 80% of the global diabetes burden as 
well as 90% of all cases of maternal and perinatal deaths and 
poor pregnancy outcomes [1]. In particular, 8 LMICs — India, 
China, Nigeria, Pakistan, Indonesia, Bangladesh, Brazil, and 
Mexico account for 55% of the global live births (70 million 
live births annually) as well as 55% of the global burden of 
diabetes (209.5 million) and should be key targets for any 
focused strategy on addressing the global burden of GDM 
pregnancies [1]. These countries have been identified as 
priority countries for all future FIGO GDM interventions.
Leave alone the developing world, even in countries 
within Europe, with their well-developed public health sys-
tems and universal health coverage; there is lack of consen-
sus on the optimal approach to testing for HIP, particularly, 
the utility of the continued use of risk-based testing versus 
universal testing. Despite the evidence that risk based test-
ing fails to identify almost half the cases, concerns continue 
to be expressed that universal testing and (consequently) 
increased diagnosis of GDM would place additional logisti-
cal and economic challenges to healthcare systems, as oral 
glucose tolerance tests (OGTT) are time-consuming and 
incur costs. On the other hand, the problem of complex 
protocols for testing based on risk factors, which places 
high demands on healthcare providers, with the consequent 
lower compliance and missed diagnosis has not been ac-
knowledged. These arguments also do not take into account 
the immediate and long term health and economic benefits 
of testing, diagnosis and management of HIP and provid-
ing post-partum preventive care to the high risk mother 
child pair and therefore screening based on risks and/or 
a GCT cannot be endorsed for either health or economic 
reasons [5]. 
Given the high rates of hyperglycemia in pregnancy 
in most populations and that selective testing based on 
known risk factors has poor sensitivity for detection of 
GDM, it seems appropriate to recommend universal rather 
than risk factor-based testing. This approach is strongly 
recommended by FIGO[1]. In addition to universal testing, 
FIGO endorses the single step approach to diagnosis and 
testing as recommended by the World Health Organiza-
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tion (WHO) and International Association of Diabetes in 
Pregnancy Study Groups (IADPSG).
In summary of the paper The International Federation 
of Gynecology and Obstetrics (FIGO) Initiative on Gesta-
tional Diabetes Mellitus: A Pragmatic Guide for Diagnosis, 
Management, and Care published in International Journal 
of Gynecology and Obstetrics 131 S3 (2015) S173–S211, to 
address the issue of GDM, FIGO recommends the following:
Public health focus: There should be greater international 
attention paid to GDM and to the links between maternal 
health and non-communicable diseases on the sustainable 
developmental goals agenda. Public health measures to in-
crease awareness, access, affordability, and acceptance of 
preconception counselling, and prenatal and postnatal ser-
vices for women of reproductive age must be prioritized [1].
Universal testing: All pregnant women should be tested 
for hyperglycemia during pregnancy using a one-step pro-
cedure and FIGO encourages all countries and its member 
associations to adapt and promote strategies to ensure this [1]. 
Criteria for diagnosis: The WHO criteria for diagnosis of 
diabetes mellitus in pregnancy and the WHO and the Inter-
national Association of Diabetes in Pregnancy Study Groups 
(IADPSG) criteria for diagnosis of GDM should be used when 
possible. Keeping in mind the resource constraints in many 
low-resource countries, alternate strategies described in the 
document should also be considered equally acceptable [1].
Diagnosis of GDM: Diagnosis should ideally be based on 
laboratory results of venous plasma samples that are properly 
collected, transported, and tested. Given the resource con-
straints in many low-resource countries, it is acceptable to 
use a plasma-calibrated handheld glucometer for diagnostic 
purposes [1].
Management of GDM: Management should be in ac-
cordance with available national resources and infrastructure 
even if the specific diagnostic and treatment protocols are not 
supported by high-quality evidence, as this is preferable to no 
care at all [1].
Lifestyle management: Nutrition counselling and physi-
cal activity should be the primary tools in the management 
of GDM. Women with GDM must receive practical nutritional 
education and counselling that will empower them to choose 
the right quantity and quality of food and level of physical 
activity. They should be advised repeatedly during pregnancy 
to continue the same healthy lifestyle after delivery to reduce 
the risk of future obesity, T2DM, and cardiovascular diseases [1].
Pharmacological management: If lifestyle modification 
alone fails to achieve glucose control, metformin, glyburide, or 
insulin should be considered as safe and effective treatment 
options for GDM during the second and third trimesters [1].
Postpartum follow-up and linkage to care: Following 
a GDM pregnancy, the postpartum period provides an impor-
tant platform to initiate beneficial health practices for both 
mother and child to reduce the future burden of several non-
communicable diseases. Obstetricians must establish links 
with family physicians, internists, pediatricians, and other 
healthcare providers to support postpartum follow-up of GDM 
mothers and their children. A follow-up program linked to the 
child’s vaccination and regular health check-up visits provides 
an opportunity for continued engagement with the high risk 
mother-child pair [1]. 
Future research: There should be greater international 
research collaboration to address the knowledge gaps to bet-
ter understand the links between maternal health and non-
communicable diseases. Evidence-based findings are urgently 
needed to provide best practice standards for testing, manage-
ment, and care of women with GDM. Cost-effectiveness models 
must be used for countries to make the best choices for testing 
and management of GDM given their specific burden of disease 
and resources [1].
THE SITUATION IN EUROPE AND NEED FOR 
EUROPEAN CONSENSUS 
Infant and maternal mortality in Europe is generally 
quite low and continues to decline, but perinatal mortality 
and morbidity remains a major concern [6]. The incidence of 
pre-term and very pre-term births, fetal growth restriction, 
and congenital anomalies has increased in many countries, 
reflecting limited achievements in preventing high risk situ-
ations. About one-third of all fetal deaths and 40% of all 
neonatal deaths in Europe were among babies born before 
28 weeks of gestation [6]. Stillbirths have also declined less 
rapidly, and in many cases their causes remain unknown. 
Increased clinical and community awareness of the risks 
associated with common pre-gestational and gestational 
medical disorders (e.g. diabetes and hypertension) and im-
plementation of best practice guidelines might improve 
management and lower associated stillbirth rates [7].
With the introduction of targeted interventions, there 
are declining rates of direct maternal deaths within Europe. 
Most maternal deaths in Europe, as elsewhere in the world, 
are directly due to hemorrhage, hypertension, thrombo-
embolic disease, sepsis and obstructed labor, the risk for 
which is considerably increased with HIP. Addressing obesity 
and HIP may help further lower maternal and newborn 
morbidity and mortality by lowering the risk of pregnancy 
complications such as pre-term births, still births, congenital 
anomalies, small and large babies which are critical prob-
lems for maternal and child health in Europe [6].
Without preventive care, almost half of women with 
gestational diabetes go on to develop type 2 diabetes and 
a significant proportion develops premature cardiovascular 
disease within 10 years of childbirth [8–10]. Children born 
to women with HIP are also at very high risk of obesity, early 
onset type 2 diabetes and cardiovascular disease whereby, 
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HIP perpetuates these conditions into the next generation 
[11–13].
Focusing on maternal obesity and HIP screening during 
pregnancy provides a unique opportunity to integrate ser-
vices which would lower traditional maternal and perinatal 
morbidity and mortality indicators and address inter-gen-
erational prevention of NCDs such as obesity, diabetes, 
hypertension and CVD. But how can we achieve this when 
we bury our heads in the sand and continue to disregard 
the basic premise of testing all pregnant women for hy-
perglycemia as alluded to earlier? It is unbelievable, that 
health care funding has not been prioritized for this and for 
targeted, preventive post-partum care and health promo-
tion for high-risk mother and child pairs.
The European Association of Perinatal Medicine (EAPM), 
the European Board and College of Obstetrics and Gyneco- 
logy (EBCOG) and the International Association of Diabetes 
in Pregnancy Study Groups (IADPSG) were amongst the first 
to endorse and support the FIGO document. 
It is about time that health planners and policy makers 
in Europe pay heed to these recommendations and take 
appropriate steps to implement the necessary actions to 
address the link between maternal health, obesity and dia-
betes as a public health priority and accelerate the imple-
mentation of the FIGO GDM initiative in Europe, through 
supportive policy actions and mobilizing resources for its 
implementation, including:
• Encouraging all countries in Europe to adapt and promote 
Universal testing of all pregnant women for hyperglyce-
mia using a one-step procedure as a minimum standard. 
• Supporting efforts to increase public awareness about 
hyperglycemia in pregnancy and its impact on maternal 
and child health; encourage preconception counseling, 
antenatal care and post-natal follow up.
• Encouraging task shifting and role based training to 
build capacity for prevention, early diagnosis, and treat-
ment of HIP and continued engagement with the high 
risk mother child pair over a prolonged time period 
linked to the child’s vaccination program and collabora-
tion between medical specialties. 
• Improving access to uninterrupted diagnostic supplies, 
medications and trained manpower for diagnosis and 
appropriate management for HIP at all levels of care at 
affordable costs keeping the pregnant women’s con-
venience in mind.
• Supporting and funding of research that fuels both 
the discovery of new tools and procedures to improve 
point of care diagnostics, monitoring and management 
of HIP and the ability to engage, counsel and track the 
mother-child pair over the long term; as well as carry 
out operational research to improve collaboration and 
efficacy in existing programs, keeping in mind the health 
care delivery realities in different parts of Europe.
Failure to act now will only prove the adage "penny wise 
and pound foolish". 
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